BTK and Bruton-type agammaglobulinemia: These experiments have successfully validated the ability of this gene therapy approach to allow for engraftment of Btk gene-edited Lin- cells into a murine model of XLA, but they do not answer the question of whether this results in correction of XLA disease phenotypes.